ClinicalTrials.Veeva

Menu
M

MaineHealth Maine Medical Center | Maine Children's Cancer Program

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cyclophosphamide
Etoposide
cyclophosphamide
Carboplatin
Vincristine Sulfate
Vincristine
Doxorubicin Hydrochloride
vincristine sulfate
Methotrexate
Cisplatin

Parent organization

This site is a part of MaineHealth Maine Medical Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 123 total trials

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling
Locally Advanced Solid Tumors
Primary CNS Tumors
Drug: Oral repotrectinib (TPX-0005)

This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger pati...

Active, not recruiting
Stage III Childhood Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma
Other: quality of life assessment
Drug: Dacarbazine(R)

This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimen...

Enrolling
Hodgkin Lymphoma
Drug: Etoposide
Drug: DTIC

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harb...

Enrolling
Multiple Myeloma
Advanced Solid Tumors
Drug: Trastuzumab and Pertuzumab
Drug: Palbociclib

Trial sponsors

C
National Cancer Institute (NCI) logo
St. Jude Children's Research Hospital logo
NYU Langone Health logo
Turning Point Therapeutics logo
A
L
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems